The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
PRAME Expression in Melanocytic Tumors
Open accessAbstract
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen that was isolated by autologous T cells in a melanoma patient. While frequent PRAME mRNA expression is well documented in cutaneous and ocular melanomas, little is known about PRAME protein expression in melanocytic tumors. In this study we examined the immunohistochemical expression of PRAME in 400 melanocytic tumors, including 155 primary and 100 metastatic melanomas, and 145 melanocytic nevi. Diffuse nuclear immunoreactivity for PRAME was found in 87% of metastatic and 83.2% of primary melanomas. Among melanoma subtypes, PRAME was diffusely expressed in 94.4% of acral melanomas, 92.5% of superficial spreading melanomas, 90% of nodular melanomas, 88.6% of lentigo maligna melanomas, and 35% of desmoplastic melanomas. When in situ and nondesmoplastic invasive melanoma components were present, PRAME expression was seen in both. Of the 140 cutaneous melanocytic nevi, 86.4% were completely negative for PRAME. Immunoreactivity for PRAME was seen, albeit usually only in a minor subpopulation of lesional melanocytes, in 13.6% of cutaneous nevi, including dysplastic nevi, common acquired nevi, traumatized/recurrent nevi, and Spitz nevi. Rare isolated junctional melanocytes with immunoreactivity for PRAME were also seen in solar lentigines and benign nonlesional skin. Our results suggest that immunohistochemical analysis for PRAME expression may be useful for diagnostic purposes to support a suspected diagnosis of melanoma. It may also be valuable for margin assessment of a known PRAME-positive melanoma, but its expression in nevi, solar lentigines, and benign nonlesional skin can represent a pitfall and merits further investigations to better assess the potential clinical utility of this marker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ikeda, H., Lethé, B., Lehmann, F., Van Baren, N., Baurain, J.-F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80426-4 · Cited by 762
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Field, M. G., Decatur, C. L., Kurtenbach, S., Gezgin, G., van der Velden, P. A., Jager, M. J., Kozak, K. N., & Harbour, J. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2071 · Cited by 293
Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers
Salmaninejad, A., Zamani, M. R., Pourvahedi, M., Golchehre, Z., Hosseini Bereshneh, A., & Rezaei, N. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1197241 · Cited by 193
Oberthuer, A., Hero, B., Spitz, R., Berthold, F., & Fischer, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0813 · Cited by 175
Field, M. G., Durante, M. A., Decatur, C. L., Tarlan, B., Oelschlager, K. M., Stone, J. F., Kuznetsoff, J. N., Bowcock, A. M., Kurtenbach, S., & Harbour, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.10962 · Cited by 126
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma
Gezgin, G., Luk, S. J., Cao, J., Doğrusöz, M., van der Steen, D. M., Hagedoorn, R. S., Krijgsman, D., van der Velden, P. A., Field, M. G., Luyten, G. P. M., et al. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.0729 · Cited by 118
Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1
Iura, K., Maekawa, A., Kohashi, K., Ishii, T., Bekki, H., Otsuka, H., Yamada, Y., Yamamoto, H., Harimaya, K., Iwamoto, Y., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.12.006 · Cited by 110
Wadelin, F. R., Fulton, J., McEwan, P., Spriggs, K. A., Emsley, J., & Heery, D. M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-226 · Cited by 96
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens
Chang, A. Y., Dao, T., Gejman, R. S., Jarvis, C. A., Scott, A., Dubrovsky, L., Mathias, M. D., Korontsvit, T., Zakhaleva, V., Curcio, M. J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92335 · Cited by 96
Pujol, J.-L., Pas, T. M. D., Rittmeyer, A., Vallières, E., Kubisa, B., Levchenko, E., Wiesemann, S. D., Masters, G. A., Shen, R. K., Tjulandin, S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.120 · Cited by 92
Cited by
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
Wermke, M., Araujo, D. M., Chatterjee, M., Tsimberidou, A. M., Holderried, T. A. W., Jazaeri, A. A., Reshef, R., Bokemeyer, C., Alsdorf, W., Wetzko, K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03650-6 · Cited by 73
Macandog, A. D. G., Catozzi, C., Capone, M., Nabinejad, A., Nanaware, P. P., Liu, S., Vinjamuri, S., Stunnenberg, J. A., Galiè, S., Jodice, M. G., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.10.006 · Cited by 40
Computer-Aided Assessment of Melanocytic Lesions by Means of a Mitosis Algorithm
Sturm, B., Creytens, D., Smits, J., Ooms, A. H. A. G., Eijken, E., Kurpershoek, E., Küsters-Vandevelde, H. V. N., Wauters, C., Blokx, W. A. M., & van der Laak, J. A. W. M. (2022) · Diagnostics · doi:10.3390/diagnostics12020436 · Cited by 13
Molecular genomic insights into melanoma associated proteins PRAME and BAP1
Nawn, D., Hassan, S. S., Hromić-Jahjefendić, A., Bhattacharya, T., Basu, P., Redwan, E. M., Barh, D., Andrade, B. S., Aljabali, A. A., Serrano-Aroca, Á., et al. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2475228 · Cited by 3
Metadata
- Authors
- Lezcano, C., Jungbluth, A. A., Nehal, K. S., Hollmann, T. J., & Busam, K. J.
- Venue
- American Journal of Surgical Pathology
- Published
- 2018-11
- Volume
- 42
- Issue
- 11
- Pages
- 1456-1465
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2884769110
- Cited by
- 417
- References
- 17
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PRAME Expression in Melanocytic Tumors. https://app.cochat.ai/papers/10.1097/pas.0000000000001134
- The paper
- Lezcano, C., Jungbluth, A. A., Nehal, K. S., Hollmann, T. J., & Busam, K. J. (2018). PRAME Expression in Melanocytic Tumors. American Journal of Surgical Pathology. https://doi.org/10.1097/pas.0000000000001134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.